美银证券发表研究报告指，华润医药(03320.HK) 去年总收入按年升5.3%至2,577亿元人民币，符合预期，毛利为407亿元人民币，按年升6.1%，毛利率达15.8%。净利润34亿元人民币，较上年同期下跌13.1%。该行表示，将集团今年、明年及2027年收入预测分别下调1%、3%及5%，毛利率预测上调1至3个百分点，其目标价由6.3元下调至6.2元，重申其评级为“买入”。(ca/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.